0
Skip to Content
Vital Biomedical
News
The Culture Desk RX
The Daily D.
Medical Joke of the Day
Donate
Contact
About
Login Account
Vital Biomedical
News
The Culture Desk RX
The Daily D.
Medical Joke of the Day
Donate
Contact
About
Login Account
Folder: HOME
Back
News
The Culture Desk RX
The Daily D.
Medical Joke of the Day
Donate
Contact
About
Login Account
FDA & Regulation, Drugs & Devices Katie Coffee 11/16/26 FDA & Regulation, Drugs & Devices Katie Coffee 11/16/26

FDA Approves Gazyva as First Drug for Primary Membranous Nephropathy

The FDA has approved Genentech's Gazyva for adults with primary membranous nephropathy, a rare autoimmune kidney disease with no previously approved drug. In a 142-patient trial, complete remission at two years was far more common than with tacrolimus, an off-label standard option.

Read More
Phillip Leblanc 10/11/26 Phillip Leblanc 10/11/26

The FDA Promises a Custom-Fit Rulebook for Rare Disease Drugs. Patients Should Read the Fine Print.

The FDA’s new Rare Disease Framework Initiative promises evidence standards tailored to tiny patient populations. What it covers, how to weigh in on October 28, and the questions it leaves open.

Read More
Newsletter Block
This newsletter signup form needs a storage option. Edit the block and enter a storage location via the Storage tab.

Subscribe

Sign up with your email address to receive news and updates.

We respect your privacy.

Thank you!

© 2026 Vital Biomedical News. Content is for informational purposes only and is not medical advice. About · Contact